Literature DB >> 23804241

Hypermethylation reduces expression of tumor-suppressor PLZF and regulates proliferation and apoptosis in non-small-cell lung cancers.

Xiaotian Wang1, Lei Wang, Shicheng Guo, Yang Bao, Yanyun Ma, Fengyang Yan, Kuan Xu, Zhiyun Xu, Li Jin, Daru Lu, Jibin Xu, Jiu-Cun Wang.   

Abstract

Deregulation of promyelocytic leukemia zinc finger protein (PLZF), a tumor suppressor gene, was reported in different types of solid tumors. This study for the first time explored the reduced expression of PLZF and its effects in non-small-cell lung cancer (NSCLC) carcinogenesis. PLZF was found to be down-regulated by 62.8% in 87.1% of 154 paired NSCLC samples by quantitative real-time PCR, and its expression was found to be associated with the sex of the patient (P=0.02). Further analysis showed that down-regulation of PLZF in 35.6% NSCLC samples (31 out of 87) was triggered by hypermethylation in the promoter region. This was validated by demethylation analysis using the A549 cell line. Dual-luciferase reporter assay indicated that CTCF binding to the promoter region could activate PLZF transcription. Overexpression of PLZF in both A549 and LTEP lung cancer cell lines was found to inhibit proliferation and increase apoptosis. Therefore, reduced expression of PLZF was found to be common in NSCLC. PLZF down-regulation was partially correlated with hypermethylation in the promoter region. Decreased levels of PLZF expression may contribute to the pathogenesis of NSCLC by promoting cell survival. Therefore, the restoration of PLZF expression may serve as a new strategy for NSCLC therapy.

Entities:  

Keywords:  BSP; MSP

Mesh:

Substances:

Year:  2013        PMID: 23804241     DOI: 10.1096/fj.13-229070

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  13 in total

1.  ZBTB16: a novel sensitive and specific biomarker for yolk sac tumor.

Authors:  Guang-Qian Xiao; Faqian Li; Pamela D Unger; Hani Katerji; Qi Yang; Loralee McMahon; David E Burstein
Journal:  Mod Pathol       Date:  2016-02-26       Impact factor: 7.842

2.  Expression of the PTEN/FOXO3a/PLZF signalling pathway in pancreatic cancer and its significance in tumourigenesis and progression.

Authors:  Qiubo Zhang; Xuanna Li; Yaqing Li; Shaojie Chen; Xiaoling Shen; Xianwen Dong; Yufei Song; Xuesong Zhang; Kaihong Huang
Journal:  Invest New Drugs       Date:  2019-05-14       Impact factor: 3.850

3.  Identification and validation of the methylation biomarkers of non-small cell lung cancer (NSCLC).

Authors:  Shicheng Guo; Fengyang Yan; Jibin Xu; Yang Bao; Ji Zhu; Xiaotian Wang; Junjie Wu; Yi Li; Weilin Pu; Yan Liu; Zhengwen Jiang; Yanyun Ma; Xiaofeng Chen; Momiao Xiong; Li Jin; Jiucun Wang
Journal:  Clin Epigenetics       Date:  2015-01-22       Impact factor: 6.551

4.  Loss of PLZF expression in prostate cancer by immunohistochemistry correlates with tumor aggressiveness and metastasis.

Authors:  Guang-Qian Xiao; Pamela Unger; Qi Yang; Yayoi Kinoshita; Kyra Singh; Loralee McMahon; Kent Nastiuk; Kai Sha; John Krolewski; David Burstein
Journal:  PLoS One       Date:  2015-03-25       Impact factor: 3.240

5.  PLZF inhibits proliferation and metastasis of gallbladder cancer by regulating IFIT2.

Authors:  Hui Shen; Ming Zhan; Yonglong Zhang; Shuai Huang; Sunwang Xu; Xince Huang; Min He; Yanhua Yao; Mohan Man; Jian Wang
Journal:  Cell Death Dis       Date:  2018-01-22       Impact factor: 8.469

6.  Tangshen formula attenuates diabetic renal injuries by upregulating autophagy via inhibition of PLZF expression.

Authors:  Hailing Zhao; Xin Li; Tingting Zhao; Haojun Zhang; Meihua Yan; Xi Dong; Pengmin Chen; Liang Ma; Ping Li
Journal:  PLoS One       Date:  2017-02-09       Impact factor: 3.240

7.  Genome-wide screen identifies a novel prognostic signature for breast cancer survival.

Authors:  Xuan Y Mao; Matthew J Lee; Jeffrey Zhu; Carissa Zhu; Sindy M Law; Antoine M Snijders
Journal:  Oncotarget       Date:  2017-02-21

8.  Crosstalk Between Prostate Cancer Cells and Tumor-Associated Fibroblasts Enhances the Malignancy by Inhibiting the Tumor Suppressor PLZF.

Authors:  Kum Hee Noh; Ae Jin Jeong; Haeri Lee; Song-Hee Lee; Eunhee Yi; Pahn-Shick Chang; Cheol Kwak; Sang-Kyu Ye
Journal:  Cancers (Basel)       Date:  2020-04-27       Impact factor: 6.639

9.  Upregulation of PLZF is Associated with Neuronal Injury in Lipopolysaccharide-Induced Neuroinflammation.

Authors:  Mingqing He; Yonghua Liu; Jiabing Shen; Chengwei Duan; Xiang Lu
Journal:  Neurochem Res       Date:  2016-08-19       Impact factor: 4.414

Review 10.  Role of PLZF as a tumor suppressor in prostate cancer.

Authors:  Yang Jin; Hatice Zeynep Nenseth; Fahri Saatcioglu
Journal:  Oncotarget       Date:  2017-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.